OncoMatch/Clinical Trials/NCT06483048
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Is NCT06483048 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Autologous MUC1-activated T-cells and Bendamustine for platinum-resistant fallopian tube carcinoma.
Treatment: Autologous MUC1-activated T-cells · Bendamustine · Cyclophosphamide — This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment (resistant). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and are made in a laboratory to recognize MUC1, a protein on the surface of tumor cells that plays a key role in tumor cell growth. These MUC1-activated T cells may help the body's immune system identify and kill MUC1 expressing ovarian tumor cells.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: MUC1 overexpression (IHC staining score > 0)
MUC1 expression in ovarian cancer tumor cells verified by immunohistochemistry (IHC) in a Clinical Laboratory Improvement Act (CLIA) laboratory. Heterogeneous tumor expression of MUC1 is acceptable. MUC1 expression by staining score greater than 0 is deemed positive for this study
Allowed: BRCA1 pathogenic mutation
Patients with BRCA1/2 mutations must have received prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor to be eligible
Allowed: BRCA2 pathogenic mutation
Patients with BRCA1/2 mutations must have received prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor to be eligible
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy
Relapsed or refractory ovarian cancer previously treated with or intolerant to at least one prior line of therapy with platinum chemotherapy
Cannot have received: MUC1-targeted therapy
Prior treatment targeting MUC1
Lab requirements
Blood counts
ANC ≥ 1500/mm^3; Lymphocyte count ≥ 1500/mm^3; Hemoglobin ≥ 8.0 g/dL; Platelet count ≥ 30,000/mm^3
Kidney function
Calculated creatinine clearance ≥ 30 ml/min using Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 2.0 mg/dL unless Gilbert's syndrome (≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN); ALT and AST ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement)
ANC ≥ 1500/mm^3; Lymphocyte count ≥ 1500/mm^3; Hemoglobin ≥ 8.0 g/dL; Platelet count ≥ 30,000/mm^3; Total bilirubin ≤ 2.0 mg/dL unless patient has documented Gilbert's syndrome (≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN); ALT and AST ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement); Calculated creatinine clearance ≥ 30 ml/min using Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Scottsdale, Arizona
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06483048 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior MUC1-targeted therapy disqualifies patients from enrollment.
Does this trial require MUC1?
Yes, MUC1 overexpression is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages